Celgene Corp. (NASDAQ:CELG) was downgraded by research analysts at Vetr from a “buy” rating to a “hold” rating in a research report issued on Monday. They currently have a $125.81 target price on the biopharmaceutical company’s stock. Vetr‘s target price suggests a potential upside of 3.04% from the company’s current price.

Several other research analysts have also issued reports on CELG. Leerink Swann reaffirmed a “market perform” rating and set a $135.00 target price (up from $125.00) on shares of Celgene Corp. in a research report on Monday, August 1st. Stifel Nicolaus reaffirmed a “buy” rating and set a $138.00 target price on shares of Celgene Corp. in a research report on Tuesday, August 2nd. Morgan Stanley reaffirmed a “hold” rating and set a $120.00 target price on shares of Celgene Corp. in a research report on Wednesday, August 3rd. BTIG Research raised Celgene Corp. from a “neutral” rating to a “buy” rating and raised their target price for the stock from $116.14 to $138.00 in a research report on Wednesday, August 3rd. Finally, Zacks Investment Research raised Celgene Corp. from a “hold” rating to a “buy” rating and set a $130.00 target price for the company in a research report on Friday, August 5th. Four research analysts have rated the stock with a hold rating and twenty-seven have given a buy rating to the company. Celgene Corp. currently has an average rating of “Buy” and an average target price of $136.62.

Analyst Recommendations for Celgene Corp. (NASDAQ:CELG)

Celgene Corp. (NASDAQ:CELG) opened at 122.13 on Monday. The firm has a market capitalization of $94.68 billion, a PE ratio of 46.38 and a beta of 1.71. Celgene Corp. has a 52-week low of $93.05 and a 52-week high of $127.00. The stock’s 50 day moving average price is $108.88 and its 200 day moving average price is $106.73.

Celgene Corp. (NASDAQ:CELG) last released its quarterly earnings data on Thursday, October 27th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.48 by $0.10. Celgene Corp. had a return on equity of 70.48% and a net margin of 19.71%. The company had revenue of $2.98 billion for the quarter, compared to the consensus estimate of $2.84 billion. During the same quarter last year, the business posted $1.23 EPS. Celgene Corp.’s revenue for the quarter was up 27.8% on a year-over-year basis. On average, analysts predict that Celgene Corp. will post $5.92 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Vetr Inc. Downgrades Celgene Corp. (CELG) to Hold” was posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this article on another domain, it was copied illegally and reposted in violation of United States and international copyright legislation. The correct version of this article can be accessed at https://www.thecerbatgem.com/2016/11/30/vetr-inc-downgrades-celgene-corp-celg-to-hold.html.

In related news, Director Gilla Kaplan sold 9,710 shares of the company’s stock in a transaction on Thursday, September 15th. The shares were sold at an average price of $106.44, for a total value of $1,033,532.40. Following the completion of the transaction, the director now directly owns 72,142 shares in the company, valued at $7,678,794.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Corp /De/ Celgene bought 800,150 shares of the business’s stock in a transaction that occurred on Monday, October 24th. The stock was bought at an average price of $14.00 per share, with a total value of $11,202,100.00. The disclosure for this purchase can be found here. 0.97% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Arete Wealth Advisors LLC raised its stake in Celgene Corp. by 0.3% in the third quarter. Arete Wealth Advisors LLC now owns 3,106 shares of the biopharmaceutical company’s stock valued at $325,000 after buying an additional 10 shares during the last quarter. Park National Corp OH raised its stake in Celgene Corp. by 0.4% in the third quarter. Park National Corp OH now owns 3,158 shares of the biopharmaceutical company’s stock valued at $330,000 after buying an additional 12 shares during the last quarter. Proficio Capital Partners LLC raised its stake in Celgene Corp. by 0.9% in the third quarter. Proficio Capital Partners LLC now owns 1,627 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 15 shares during the last quarter. Reynders McVeigh Capital Management LLC raised its stake in Celgene Corp. by 0.4% in the third quarter. Reynders McVeigh Capital Management LLC now owns 6,265 shares of the biopharmaceutical company’s stock valued at $655,000 after buying an additional 24 shares during the last quarter. Finally, Jolley Asset Management LLC raised its stake in Celgene Corp. by 2.1% in the third quarter. Jolley Asset Management LLC now owns 1,240 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 25 shares during the last quarter. Institutional investors own 76.43% of the company’s stock.

About Celgene Corp.

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Receive News & Stock Ratings for Celgene Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corp. and related stocks with our FREE daily email newsletter.